REPURPOSING OF AN APPROVED DRUG SPECIFIC FOR VARIOUS NEUROLOGICAL CONDITIONS
Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trade marked its repurposed Exenatide as Presendin™. Following a successful Phase II clinical trial in May 2020, the Company will now progress Presendin™ into a Phase III registration study in IIH.
- Birmingham researcher awarded £1.68m to fund research in ‘raised brain pressure’ 05/03/2020
- Rare Disease Day 10/02/2020
- Nature Communications: Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics 30/01/2020
- Health Kick Podcast: Investing in repurposed drugs, combating intracranial pressure and why Invex caught NASA’s eye 05/12/2019
- Q & A with Professor Alexandra Sinclair 21/11/2019